Assessment of Therapeutic Potential of Stigma Maydis (Cornsilk) on Metabolic Syndrome

Lipid profile will be assessed before and after the trial.,waist circumference will be measured before and after the trial.,Blood pressure will be assessed before and after the trial.,Fasting glucose level will be assessed before and after the trial.

Over the past two decades, there has been an increase in the number of people with nutrition
 related maladies due to changes in their dietary habits and lifestyle. Cardiovascular
 disease, type 2 diabetes, metabolic syndrome, obesity, and cancer have emerged as prominent
 contributors to both illness and death, particularly as the population continues to age. The
 mortality figures for cardiovascular disease and diabetes varied between 179.8 to 765.2 per
 100,000 individuals, with the most elevated rates observed in poor nations. The occurrence of
 metabolic syndrome was markedly prevalent, spanning from 19% to 45%. The incidence of
 overweight and obesity (defined by a body mass index ≥25 kg/m2) has surged to concerning
 levels across many countries in the region, ranging from 25% to 82%, with a higher occurrence
 among women. Due to side effects of allopathic treatments and increase in nutrition knowledge
 people are more inclined to natural therapies. Subsequently, corn silk with nutraceutical
 properties may provide an effective alternative therapy to alleviate symptoms and decrease
 healthcare loss. Cornsilk, the often-overlooked byproduct of maize cultivation, is rich in
 bioactive compounds, including flavonoids, polysaccharides, and vitamins, cornsilk has shown
 promising effects in promoting health and wellness.